# Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

> **NCT00697541** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 20 (actual)

## Conditions studied

- Erythematous Rosacea

## Interventions

- **DRUG:** 0.18% COL-118 facial gel (1.8 mg brimonidine)
- **DRUG:** 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
- **DRUG:** Advanced Eye Relief
- **DRUG:** COL-118 facial gel vehicle

## Key facts

- **NCT ID:** NCT00697541
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697541, "Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00697541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*